Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort - Concepedia

Concepedia

Publication | Open Access

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

DOI Full Paper Access

123

Citations

18

References

2016

Year

Matthew R. Smith, Emmanuel S. Antonarakis, Charles J. Ryan, William L. Berry, Neal D. Shore, Glenn Liu, Joshi J. Alumkal, Celestia S. Higano, Edna Chow Maneval, Rajesh Bandekar,

European Urology

References

	Year	Citations

Page 1